Treats insomnia characterized. ANDA 202510, held by Strides Pharma Intl. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 202510 (Doxepin Hydrochloride), held by Strides Pharma Intl, was first approved by FDA on Jul 24, 2020, with 2 approved supplements and 0 published complete response letters.
Doxepin Tablets are indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 24, 2020 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 3MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 6MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
| Sep 22, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 22, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 24, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters